Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab.

Cathy Mireille Melong Pianta Taleng Kim LauperBenoit GilbertTim CunninghamRomain GuemaraLaure BrulhartDiana DanDelphine Sophie Courvoisier Axel Finckh

Published in: RMD open (2021)

While the incidence of symptoms compatible with COVID-19 was overall similar in patients receiving RTX or IFX, the incidence of severe COVID-19 tended to be higher in the RTX group.

Keyphrases

coronavirus disease
sars cov
risk factors
respiratory syndrome coronavirus
diffuse large b cell lymphoma
ulcerative colitis
depressive symptoms
drug induced